Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $118000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 5.6% to $118000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $621000.0 through Dec 2025, up 16.29% year-over-year, with the annual reading at $621000.0 for FY2025, 16.29% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $118000.0 at Lexicon Pharmaceuticals, down from $151000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $176000.0 in Q1 2025, with the low at $112000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $142416.7, with a median of $144000.0 recorded in 2023.
  • Peak annual rise in Depreciation & Amortization (CF) hit 28.57% in 2024, while the deepest fall reached 16.56% in 2024.
  • Over 3 years, Depreciation & Amortization (CF) stood at $147000.0 in 2023, then decreased by 14.97% to $125000.0 in 2024, then fell by 5.6% to $118000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $118000.0, $151000.0, and $176000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.